NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

NOT YET RECRUITING

Identifier: CI-TRIAL-00120588
Entity page: /trial/NCT07178730 ↗
Edges: 4

Neighbours: 2 cancers2 drugs
Drawn: 4 of 4 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer condition of …CONDITION_OFderived2 of 2
← condition of	Malignant Breast Neoplasm registry condition “Breast Cancer” mapped CURATED_EXACT	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
← condition of	Triple-Negative Breast Carcinoma registry condition “Triple-negative Breast Cancer” mapped ALIAS

NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer intervention of …INTERVENTION_OFderived2 of 2
← intervention of	Pembrolizumabmonoclonal antibody registry intervention “Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Sacituzumab Govitecanadc registry intervention “Sacituzumab govitecan” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer intervention of …INTERVENTION_OFderived2 of 2

← intervention of

Pembrolizumabmonoclonal antibody

registry intervention “Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →